<DOC>
	<DOCNO>NCT00649480</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan balsalazide disodium 750 mg capsule Salix Colazal® 750 mg capsule follow single , oral 2250 mg ( 3 x 750 mg ) dose administration feed condition .</brief_summary>
	<brief_title>Fed Study Balsalazide Disodium Capsules 750 mg Colazal® Capsules 750 mg</brief_title>
	<detailed_description>This open-label , single dose , randomize , two-period , two-treatment , two-sequence , crossover study conduct investigate bioequivalence two formulation balsalazide disodium 750 mg capsule non-fasting condition . The study conduct 60 ( 60 complete ) healthy adult accordance Protocol No . BALS-06128 ( Version 22 December 2006 ) . In study period , single , oral 2250 mg dose ( 3 x 750 mg capsule ) administer subject follow overnight fast least 10 hour . The test formulation Mylan Pharmaceuticals Inc. 's Balsalazide Disodium Capsules , 750 mg reference formulation Colazal® 750 mg capsule ( manufactured Salix Pharmaceuticals , Inc. ) . The subject receive test product one study period reference product study period . Drug administration occur accord dose randomization schedule ( see Appendix 16.1.7 ) . There 7-day washout interval treatment .</detailed_description>
	<mesh_term>Balsalazide</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Age:18 year older Sex : Male and/or nonpregnant , nonlactating female Women childbearing potential negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test perform within 21 day prior start study even prior dose administration An additional serum ( βHCG ) pregnancy test perform upon completion study Women childbearing potential require practice abstinence use acceptable form contraception throughout duration study No hormonal contraceptive hormonal replacement therapy permit study Acceptable form contraception include follow intrauterine device place least 3 month prior start study remain place study period barrier method contain use conjunction spermicidal agent surgical sterilization Women consider childbearing potential one follow report documented medical history postmenopausal absence menses least one ( 1 ) year bilateral oophorectomy without hysterectomy absence bleed least 6 month total hysterectomy During course study study screen study exit include washout period men woman childbearing potential must use spermicide contain barrier method contraception addition current contraceptive method Weight : At least ( 132 lb ) men ( 106 lb ) woman subject Body Mass Index less equal 30 great equal 19 All subject judge normal healthy prestudy medical evaluation ( physical examination laboratory evaluation Hepatitis B Hepatitis C test HIV test 12lead ECG urine drug screen include amphetamine barbiturate benzodiazepine cannabinoid cocaine opiate phencyclidine methadone ) perform within 21 day initial dose study medication Institutionalized subject use Use tobaccocontaining product within 1 year start study Ingestion alcoholic caffeine xanthine contain food beverage within 48 hour prior initial dose study medication Ingestion vitamins herbal product within 7 day prior initial dose study medication Any recent significant change dietary exercise habit A positive test drug include urine drug screen History drug alcohol abuse Use prescription overthecounter medication within 14 day prior initial dose study medication Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication History significant cardiovascular hepatic renal pulmonary hematologic gastrointestinal endocrine immunologic dermatologic neurologic disease Acute illness time either prestudy medical evaluation dose A positive HIV hepatitis B hepatitis C test Abnormal clinically significant laboratory test result Clinically significant deviation Guide Clinically Relevant Abnormal clinically relevant ECG trace Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication Subjects receive investigational drug within 30 day prior initial dose study medication Allergy hypersensitivity balsalazide disodium salicylate related product History difficulty swallow gastrointestinal disease could affect drug absorption Consumption grapefruit grapefruit containing product within 7 day drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>